Immune Design plans to price initial public offering of common stock

Proceeds to support product development, including clinical trials

By Susanna Moon

Chicago, June 23 – Immune Design Corp. plans to price an initial public offering of common stock, according to an S-1 filing with the Securities and Exchange Commission.

Proceeds will be used to support continued development of the company’s product candidates, including into phase 2 clinical trials. Proceeds also will be used to fund working capital and for general corporate purposes, including development programs, early stage research and development and continued development of the DCVex and GLAAS platform technologies.

Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are the underwriters.

The company has applied to list its shares for trading on Nasdaq under the symbol “IMDZ.”

Immune Design is a clinical-stage immuno-therapy company based in Seattle with next-generation in vivo approaches designed to enable the body’s immune system to fight disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.